APO Research
Talk to an analyst

APO RESEARCH · REPORT

TKI for Chronic Myeloid Leukemia

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global TKI for Chronic Myeloid Leukemia Market Analysis and Forecast 2026-2032

27 December 2025203 pages

Choose your research edition.

Industry ResearchTKI for Chronic Myeloid Leukemia Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal TKI for Chronic Myeloid Leukemia Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal TKI for Chronic Myeloid Leukemia Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal TKI for Chronic Myeloid Leukemia Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal TKI for Chronic Myeloid Leukemia Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global TKI for Chronic Myeloid Leukemia market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for TKI for Chronic Myeloid Leukemia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for TKI for Chronic Myeloid Leukemia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for TKI for Chronic Myeloid Leukemia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for TKI for Chronic Myeloid Leukemia is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of TKI for Chronic Myeloid Leukemia include Apotex, Bristol Myers Squibb, Dr. Reddy's Laboratories, Eugia Pharma, Hetero, Lupin, Mylan, Novartis and Pfizer, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for TKI for Chronic Myeloid Leukemia, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of TKI for Chronic Myeloid Leukemia, also provides the sales of main regions and countries. Of the upcoming market potential for TKI for Chronic Myeloid Leukemia, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the TKI for Chronic Myeloid Leukemia sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global TKI for Chronic Myeloid Leukemia market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for TKI for Chronic Myeloid Leukemia sales, projected growth trends, production technology, application and end-user industry.

TKI for Chronic Myeloid Leukemia Segment by Company

Apotex

Bristol Myers Squibb

Dr. Reddy's Laboratories

Eugia Pharma

Hetero

Lupin

Mylan

Novartis

Pfizer

Sawai Pharmaceutical

Sun Pharmaceuticals

Takeda Pharmaceuticals

Teva

Hansoh Pharmaceutical

Lunan Pharmaceutical

Qilu Pharmaceutical

CSPC Ouyi Pharmaceutical

Suzhou Thery Pharmaceutical

Chia Tai Tianqing Pharmaceutical

TKI for Chronic Myeloid Leukemia Segment by Type

Imatinib

Ponatinib

Nilotinib

Flumatinib

Dasatinib

Bosutinib

Asciminib

Other

TKI for Chronic Myeloid Leukemia Segment by Application

Hospitals and clinics

Pharmacies

Others

TKI for Chronic Myeloid Leukemia Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global TKI for Chronic Myeloid Leukemia market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of TKI for Chronic Myeloid Leukemia and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of TKI for Chronic Myeloid Leukemia.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of TKI for Chronic Myeloid Leukemia in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of TKI for Chronic Myeloid Leukemia manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, TKI for Chronic Myeloid Leukemia sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global TKI for Chronic Myeloid Leukemia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Imatinib Major Manufacturers Table 3. Ponatinib Major Manufacturers Table 4. Nilotinib Major Manufacturers Table 5. Flumatinib Major Manufacturers Table 6. Dasatinib Major Manufacturers Table 7. Bosutinib Major Manufacturers Table 8. Asciminib Major Manufacturers Table 9. Other Major Manufacturers Table 10. Global TKI for Chronic Myeloid Leukemia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 11. Hospitals and clinics Major Manufacturers Table 12. Pharmacies Major Manufacturers Table 13. Others Major Manufacturers Table 14. TKI for Chronic Myeloid Leukemia Industry Trends Table 15. TKI for Chronic Myeloid Leukemia Industry Drivers Table 16. TKI for Chronic Myeloid Leukemia Industry Opportunities and Challenges Table 17. TKI for Chronic Myeloid Leukemia Industry Restraints Table 18. Global TKI for Chronic Myeloid Leukemia Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global TKI for Chronic Myeloid Leukemia Revenue by Region (2021-2026) & (US$ Million) Table 20. Global TKI for Chronic Myeloid Leukemia Revenue by Region (2027-2032) & (US$ Million) Table 21. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Region (2021-2026) Table 22. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Region (2027-2032) Table 23. Global TKI for Chronic Myeloid Leukemia Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 24. Global TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026) & (K Units) Table 25. Global TKI for Chronic Myeloid Leukemia Sales by Region (2027-2032) & (K Units) Table 26. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2021-2026) Table 27. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2027-2032) Table 28. Global TKI for Chronic Myeloid Leukemia Revenue by Manufacturers (US$ Million) & (2021-2026) Table 29. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Manufacturers (2021-2026) Table 30. Global TKI for Chronic Myeloid Leukemia Sales by Manufacturers (US$ Million) & (2021-2026) Table 31. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Manufacturers (2021-2026) Table 32. Global TKI for Chronic Myeloid Leukemia Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 33. Global TKI for Chronic Myeloid Leukemia Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 34. Global TKI for Chronic Myeloid Leukemia Key Manufacturers Manufacturing Sites & Headquarters Table 35. Global TKI for Chronic Myeloid Leukemia Manufacturers, Product Type & Application Table 36. Global TKI for Chronic Myeloid Leukemia Manufacturers' Establishment Date Table 37. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 38. Global TKI for Chronic Myeloid Leukemia by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global TKI for Chronic Myeloid Leukemia Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & (US$ Million) Table 41. Global TKI for Chronic Myeloid Leukemia Revenue by Type (2027-2032) & (US$ Million) Table 42. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2026) Table 43. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2027-2032) Table 44. Global TKI for Chronic Myeloid Leukemia Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 45. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 46. Global TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 47. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2026) Table 48. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2027-2032) Table 49. Global TKI for Chronic Myeloid Leukemia Price by Type (2021-2026) & (US$/Unit) Table 50. Global TKI for Chronic Myeloid Leukemia Price by Type (2027-2032) & (US$/Unit) Table 51. Global TKI for Chronic Myeloid Leukemia Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & (US$ Million) Table 53. Global TKI for Chronic Myeloid Leukemia Revenue by Application (2027-2032) & (US$ Million) Table 54. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application (2021-2026) Table 55. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application (2027-2032) Table 56. Global TKI for Chronic Myeloid Leukemia Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 57. Global TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 58. Global TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 59. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2026) Table 60. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2027-2032) Table 61. Global TKI for Chronic Myeloid Leukemia Price by Application (2021-2026) & (US$/Unit) Table 62. Global TKI for Chronic Myeloid Leukemia Price by Application (2027-2032) & (US$/Unit) Table 63. Apotex Company Information Table 64. Apotex Business Overview Table 65. Apotex TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Apotex TKI for Chronic Myeloid Leukemia Product Portfolio Table 67. Apotex Recent Development Table 68. Bristol Myers Squibb Company Information Table 69. Bristol Myers Squibb Business Overview Table 70. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolio Table 72. Bristol Myers Squibb Recent Development Table 73. Dr. Reddy's Laboratories Company Information Table 74. Dr. Reddy's Laboratories Business Overview Table 75. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolio Table 77. Dr. Reddy's Laboratories Recent Development Table 78. Eugia Pharma Company Information Table 79. Eugia Pharma Business Overview Table 80. Eugia Pharma TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolio Table 82. Eugia Pharma Recent Development Table 83. Hetero Company Information Table 84. Hetero Business Overview Table 85. Hetero TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Hetero TKI for Chronic Myeloid Leukemia Product Portfolio Table 87. Hetero Recent Development Table 88. Lupin Company Information Table 89. Lupin Business Overview Table 90. Lupin TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Lupin TKI for Chronic Myeloid Leukemia Product Portfolio Table 92. Lupin Recent Development Table 93. Mylan Company Information Table 94. Mylan Business Overview Table 95. Mylan TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Mylan TKI for Chronic Myeloid Leukemia Product Portfolio Table 97. Mylan Recent Development Table 98. Novartis Company Information Table 99. Novartis Business Overview Table 100. Novartis TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Novartis TKI for Chronic Myeloid Leukemia Product Portfolio Table 102. Novartis Recent Development Table 103. Pfizer Company Information Table 104. Pfizer Business Overview Table 105. Pfizer TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Pfizer TKI for Chronic Myeloid Leukemia Product Portfolio Table 107. Pfizer Recent Development Table 108. Sawai Pharmaceutical Company Information Table 109. Sawai Pharmaceutical Business Overview Table 110. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 112. Sawai Pharmaceutical Recent Development Table 113. Sun Pharmaceuticals Company Information Table 114. Sun Pharmaceuticals Business Overview Table 115. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio Table 117. Sun Pharmaceuticals Recent Development Table 118. Takeda Pharmaceuticals Company Information Table 119. Takeda Pharmaceuticals Business Overview Table 120. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio Table 122. Takeda Pharmaceuticals Recent Development Table 123. Teva Company Information Table 124. Teva Business Overview Table 125. Teva TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Teva TKI for Chronic Myeloid Leukemia Product Portfolio Table 127. Teva Recent Development Table 128. Hansoh Pharmaceutical Company Information Table 129. Hansoh Pharmaceutical Business Overview Table 130. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 132. Hansoh Pharmaceutical Recent Development Table 133. Lunan Pharmaceutical Company Information Table 134. Lunan Pharmaceutical Business Overview Table 135. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 137. Lunan Pharmaceutical Recent Development Table 138. Qilu Pharmaceutical Company Information Table 139. Qilu Pharmaceutical Business Overview Table 140. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 142. Qilu Pharmaceutical Recent Development Table 143. CSPC Ouyi Pharmaceutical Company Information Table 144. CSPC Ouyi Pharmaceutical Business Overview Table 145. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 147. CSPC Ouyi Pharmaceutical Recent Development Table 148. Suzhou Thery Pharmaceutical Company Information Table 149. Suzhou Thery Pharmaceutical Business Overview Table 150. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 151. Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 152. Suzhou Thery Pharmaceutical Recent Development Table 153. Chia Tai Tianqing Pharmaceutical Company Information Table 154. Chia Tai Tianqing Pharmaceutical Business Overview Table 155. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 156. Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio Table 157. Chia Tai Tianqing Pharmaceutical Recent Development Table 158. North America TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & (US$ Million) Table 159. North America TKI for Chronic Myeloid Leukemia Revenue by Type (2027-2032) & (US$ Million) Table 160. North America TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 161. North America TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 162. North America TKI for Chronic Myeloid Leukemia Sales Price by Type (2021-2026) & (US$/Unit) Table 163. North America TKI for Chronic Myeloid Leukemia Sales Price by Type (2027-2032) & (US$/Unit) Table 164. North America TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & (US$ Million) Table 165. North America TKI for Chronic Myeloid Leukemia Revenue by Application (2027-2032) & (US$ Million) Table 166. North America TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 167. North America TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 168. North America TKI for Chronic Myeloid Leukemia Sales Price by Application (2021-2026) & (US$/Unit) Table 169. North America TKI for Chronic Myeloid Leukemia Sales Price by Application (2027-2032) & (US$/Unit) Table 170. North America TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 171. North America TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 172. North America TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 173. North America TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 174. North America TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 175. North America TKI for Chronic Myeloid Leukemia Sales by Country (2027-2032) & (K Units) Table 176. North America TKI for Chronic Myeloid Leukemia Sales Price by Country (2021-2026) & (US$/Unit) Table 177. North America TKI for Chronic Myeloid Leukemia Sales Price by Country (2027-2032) & (US$/Unit) Table 178. United States TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 179. Canada TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 180. Mexico TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 181. Europe TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & (US$ Million) Table 182. Europe TKI for Chronic Myeloid Leukemia Revenue by Type (2027-2032) & (US$ Million) Table 183. Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 184. Europe TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 185. Europe TKI for Chronic Myeloid Leukemia Sales Price by Type (2021-2026) & (US$/Unit) Table 186. Europe TKI for Chronic Myeloid Leukemia Sales Price by Type (2027-2032) & (US$/Unit) Table 187. Europe TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & (US$ Million) Table 188. Europe TKI for Chronic Myeloid Leukemia Revenue by Application (2027-2032) & (US$ Million) Table 189. Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 190. Europe TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 191. Europe TKI for Chronic Myeloid Leukemia Sales Price by Application (2021-2026) & (US$/Unit) Table 192. Europe TKI for Chronic Myeloid Leukemia Sales Price by Application (2027-2032) & (US$/Unit) Table 193. Europe TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 194. Europe TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 195. Europe TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 196. Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 197. Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 198. Europe TKI for Chronic Myeloid Leukemia Sales by Country (2027-2032) & (K Units) Table 199. Europe TKI for Chronic Myeloid Leukemia Sales Price by Country (2021-2026) & (US$/Unit) Table 200. Europe TKI for Chronic Myeloid Leukemia Sales Price by Country (2027-2032) & (US$/Unit) Table 201. Germany TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 202. France TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 203. U.K. TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 204. Italy TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 205. Russia TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 206. Spain TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 207. Netherlands TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 208. Switzerland TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 209. Sweden TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 210. Poland TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 211. China TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & (US$ Million) Table 212. China TKI for Chronic Myeloid Leukemia Revenue by Type (2027-2032) & (US$ Million) Table 213. China TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 214. China TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 215. China TKI for Chronic Myeloid Leukemia Sales Price by Type (2021-2026) & (US$/Unit) Table 216. China TKI for Chronic Myeloid Leukemia Sales Price by Type (2027-2032) & (US$/Unit) Table 217. China TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & (US$ Million) Table 218. China TKI for Chronic Myeloid Leukemia Revenue by Application (2027-2032) & (US$ Million) Table 219. China TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 220. China TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 221. China TKI for Chronic Myeloid Leukemia Sales Price by Application (2021-2026) & (US$/Unit) Table 222. China TKI for Chronic Myeloid Leukemia Sales Price by Application (2027-2032) & (US$/Unit) Table 223. Asia TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & (US$ Million) Table 224. Asia TKI for Chronic Myeloid Leukemia Revenue by Type (2027-2032) & (US$ Million) Table 225. Asia TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 226. Asia TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 227. Asia TKI for Chronic Myeloid Leukemia Sales Price by Type (2021-2026) & (US$/Unit) Table 228. Asia TKI for Chronic Myeloid Leukemia Sales Price by Type (2027-2032) & (US$/Unit) Table 229. Asia TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & (US$ Million) Table 230. Asia TKI for Chronic Myeloid Leukemia Revenue by Application (2027-2032) & (US$ Million) Table 231. Asia TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 232. Asia TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 233. Asia TKI for Chronic Myeloid Leukemia Sales Price by Application (2021-2026) & (US$/Unit) Table 234. Asia TKI for Chronic Myeloid Leukemia Sales Price by Application (2027-2032) & (US$/Unit) Table 235. Asia TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 236. Asia TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 237. Asia TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 238. Asia TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 239. Asia TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 240. Asia TKI for Chronic Myeloid Leukemia Sales by Country (2027-2032) & (K Units) Table 241. Asia TKI for Chronic Myeloid Leukemia Sales Price by Country (2021-2026) & (US$/Unit) Table 242. Asia TKI for Chronic Myeloid Leukemia Sales Price by Country (2027-2032) & (US$/Unit) Table 243. Japan TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 244. South Korea TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 245. India TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 246. Australia TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 247. Taiwan TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 248. Southeast Asia TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 249. SAMEA TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2026) & (US$ Million) Table 250. SAMEA TKI for Chronic Myeloid Leukemia Revenue by Type (2027-2032) & (US$ Million) Table 251. SAMEA TKI for Chronic Myeloid Leukemia Sales by Type (2021-2026) & (K Units) Table 252. SAMEA TKI for Chronic Myeloid Leukemia Sales by Type (2027-2032) & (K Units) Table 253. SAMEA TKI for Chronic Myeloid Leukemia Sales Price by Type (2021-2026) & (US$/Unit) Table 254. SAMEA TKI for Chronic Myeloid Leukemia Sales Price by Type (2027-2032) & (US$/Unit) Table 255. SAMEA TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2026) & (US$ Million) Table 256. SAMEA TKI for Chronic Myeloid Leukemia Revenue by Application (2027-2032) & (US$ Million) Table 257. SAMEA TKI for Chronic Myeloid Leukemia Sales by Application (2021-2026) & (K Units) Table 258. SAMEA TKI for Chronic Myeloid Leukemia Sales by Application (2027-2032) & (K Units) Table 259. SAMEA TKI for Chronic Myeloid Leukemia Sales Price by Application (2021-2026) & (US$/Unit) Table 260. SAMEA TKI for Chronic Myeloid Leukemia Sales Price by Application (2027-2032) & (US$/Unit) Table 261. SAMEA TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 262. SAMEA TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 263. SAMEA TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 264. SAMEA TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 265. SAMEA TKI for Chronic Myeloid Leukemia Sales by Country (2021-2026) & (K Units) Table 266. SAMEA TKI for Chronic Myeloid Leukemia Sales by Country (2027-2032) & (K Units) Table 267. SAMEA TKI for Chronic Myeloid Leukemia Sales Price by Country (2021-2026) & (US$/Unit) Table 268. SAMEA TKI for Chronic Myeloid Leukemia Sales Price by Country (2027-2032) & (US$/Unit) Table 269. Brazil TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 270. Argentina TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 271. Chile TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 272. Colombia TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 273. Peru TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 274. Saudi Arabia TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 275. Israel TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 276. UAE TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 277. Turkey TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 278. Iran TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 279. Egypt TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Table 280. Key Raw Materials Table 281. Raw Materials Key Suppliers Table 282. TKI for Chronic Myeloid Leukemia Distributors List Table 283. TKI for Chronic Myeloid Leukemia Customers List Table 284. Research Programs/Design for This Report Table 285. Authors List of This Report Table 286. Secondary Sources Table 287. Primary Sources List of Figures Figure 1. TKI for Chronic Myeloid Leukemia Image Figure 2. Global TKI for Chronic Myeloid Leukemia Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global TKI for Chronic Myeloid Leukemia Market Size Share 2021 VS 2025 VS 2032 Figure 4. Imatinib Image Figure 5. Ponatinib Image Figure 6. Nilotinib Image Figure 7. Flumatinib Image Figure 8. Dasatinib Image Figure 9. Bosutinib Image Figure 10. Asciminib Image Figure 11. Other Image Figure 12. Global TKI for Chronic Myeloid Leukemia Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global TKI for Chronic Myeloid Leukemia Market Size Share 2021 VS 2025 VS 2032 Figure 14. Hospitals and clinics Image Figure 15. Pharmacies Image Figure 16. Others Image Figure 17. Global TKI for Chronic Myeloid Leukemia Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global TKI for Chronic Myeloid Leukemia Revenue (2021-2032) & (US$ Million) Figure 19. Global TKI for Chronic Myeloid Leukemia Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Region: 2025 Versus 2032 Figure 21. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Region (2021-2032) Figure 22. Global TKI for Chronic Myeloid Leukemia Sales (2021-2032) & (K Units) Figure 23. Global TKI for Chronic Myeloid Leukemia Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 24. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2021-2032) Figure 25. US & Canada & Mexico TKI for Chronic Myeloid Leukemia Sales YoY (2021-2032) & (K Units) Figure 26. Europe TKI for Chronic Myeloid Leukemia Sales YoY (2021-2032) & (K Units) Figure 27. China TKI for Chronic Myeloid Leukemia Sales YoY (2021-2032) & (K Units) Figure 28. Asia (Excluding China) TKI for Chronic Myeloid Leukemia Sales YoY (2021-2032) & (K Units) Figure 29. South America, Middle East and Africa TKI for Chronic Myeloid Leukemia Sales YoY (2021-2032) & (K Units) Figure 30. Global TKI for Chronic Myeloid Leukemia Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 31. Global TKI for Chronic Myeloid Leukemia Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 32. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Global TKI for Chronic Myeloid Leukemia Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 35. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2032) Figure 36. Global TKI for Chronic Myeloid Leukemia Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 38. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2032) Figure 39. Global TKI for Chronic Myeloid Leukemia Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 40. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 41. Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application (2021-2032) Figure 42. Global TKI for Chronic Myeloid Leukemia Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 43. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 44. Global TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2032) Figure 45. North America TKI for Chronic Myeloid Leukemia Revenue Share by Type (2021-2032) Figure 46. North America TKI for Chronic Myeloid Leukemia Sales Share by Type (2021-2032) Figure 47. North America TKI for Chronic Myeloid Leukemia Revenue Share by Application (2021-2032) Figure 48. North America TKI for Chronic Myeloid Leukemia Sales Share by Application (2021-2032) Figure 49. North America TKI for Chronic Myeloid Leukemia Revenue Share by Country (2021-2032) Figure 50. North America TKI for Chronic Myeloid Leukemia Sales Share by Country (2021-2032) Figure 51. Europe TKI for Chronic Myeloid Leukemia Revenue Share by Type (2021-2032) Figure 52. Europe TKI for Chronic Myeloid Leukemia Sales Share by Type (2021-2032) Figure 53. Europe TKI for Chronic Myeloid Leukemia Revenue Share by Application (2021-2032) Figure 54. Europe TKI for Chronic Myeloid Leukemia Sales Share by Application (2021-2032) Figure 55. Europe TKI for Chronic Myeloid Leukemia Revenue Share by Country (2021-2032) Figure 56. Europe TKI for Chronic Myeloid Leukemia Sales Share by Country (2021-2032) Figure 57. China TKI for Chronic Myeloid Leukemia Revenue Share by Type (2021-2032) Figure 58. China TKI for Chronic Myeloid Leukemia Sales Share by Type (2021-2032) Figure 59. China TKI for Chronic Myeloid Leukemia Revenue Share by Application (2021-2032) Figure 60. China TKI for Chronic Myeloid Leukemia Sales Share by Application (2021-2032) Figure 61. Asia TKI for Chronic Myeloid Leukemia Revenue Share by Type (2021-2032) Figure 62. Asia TKI for Chronic Myeloid Leukemia Sales Share by Type (2021-2032) Figure 63. Asia TKI for Chronic Myeloid Leukemia Revenue Share by Application (2021-2032) Figure 64. Asia TKI for Chronic Myeloid Leukemia Sales Share by Application (2021-2032) Figure 65. Asia TKI for Chronic Myeloid Leukemia Revenue Share by Country (2021-2032) Figure 66. Asia TKI for Chronic Myeloid Leukemia Sales Share by Country (2021-2032) Figure 67. SAMEA TKI for Chronic Myeloid Leukemia Revenue Share by Type (2021-2032) Figure 68. SAMEA TKI for Chronic Myeloid Leukemia Sales Share by Type (2021-2032) Figure 69. SAMEA TKI for Chronic Myeloid Leukemia Revenue Share by Application (2021-2032) Figure 70. SAMEA TKI for Chronic Myeloid Leukemia Sales Share by Application (2021-2032) Figure 71. SAMEA TKI for Chronic Myeloid Leukemia Revenue Share by Country (2021-2032) Figure 72. SAMEA TKI for Chronic Myeloid Leukemia Sales Share by Country (2021-2032) Figure 73. TKI for Chronic Myeloid Leukemia Value Chain Figure 74. Manufacturing Cost Structure Figure 75. TKI for Chronic Myeloid Leukemia Production Mode & Process Figure 76. Direct Comparison with Distribution Share Figure 77. Distributors Profiles Figure 78. Years Considered Figure 79. Research Process Figure 80. Key Executives Interviewed

Scope & coverage.

Types
  • Imatinib
  • Ponatinib
  • Nilotinib
  • Flumatinib
  • Dasatinib
  • Bosutinib
  • Asciminib
  • Other
Applications
  • Hospitals and clinics
  • Pharmacies
  • Others
Companies covered
  • Apotex
  • Bristol Myers Squibb
  • Dr. Reddy's Laboratories
  • Eugia Pharma
  • Hetero
  • Lupin
  • Mylan
  • Novartis
  • Pfizer
  • Sawai Pharmaceutical
  • Sun Pharmaceuticals
  • Takeda Pharmaceuticals
  • Teva
  • Hansoh Pharmaceutical
  • Lunan Pharmaceutical
  • Qilu Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Suzhou Thery Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 TKI for Chronic Myeloid Leukemia Market by Type
  3. 1.2.1 Global TKI for Chronic Myeloid Leukemia Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Imatinib
  5. 1.2.3 Ponatinib
  6. 1.2.4 Nilotinib
  7. 1.2.5 Flumatinib
  8. 1.2.6 Dasatinib
  9. 1.2.7 Bosutinib
  10. 1.2.8 Asciminib
  11. 1.2.9 Other
  12. 1.3 TKI for Chronic Myeloid Leukemia Market by Application
  13. 1.3.1 Global TKI for Chronic Myeloid Leukemia Market Size by Application, 2021 VS 2025 VS 2032
  14. 1.3.2 Hospitals and clinics
  15. 1.3.3 Pharmacies
  16. 1.3.4 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 TKI for Chronic Myeloid Leukemia Market Dynamics
  1. 2.1 TKI for Chronic Myeloid Leukemia Industry Trends
  2. 2.2 TKI for Chronic Myeloid Leukemia Industry Drivers
  3. 2.3 TKI for Chronic Myeloid Leukemia Industry Opportunities and Challenges
  4. 2.4 TKI for Chronic Myeloid Leukemia Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global TKI for Chronic Myeloid Leukemia Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global TKI for Chronic Myeloid Leukemia Revenue by Region
  3. 3.2.1 Global TKI for Chronic Myeloid Leukemia Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global TKI for Chronic Myeloid Leukemia Revenue by Region (2021-2026)
  5. 3.2.3 Global TKI for Chronic Myeloid Leukemia Revenue by Region (2027-2032)
  6. 3.2.4 Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Region (2021-2032)
  7. 3.3 Global TKI for Chronic Myeloid Leukemia Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global TKI for Chronic Myeloid Leukemia Sales by Region
  9. 3.4.1 Global TKI for Chronic Myeloid Leukemia Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global TKI for Chronic Myeloid Leukemia Sales by Region (2021-2026)
  11. 3.4.3 Global TKI for Chronic Myeloid Leukemia Sales by Region (2027-2032)
  12. 3.4.4 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global TKI for Chronic Myeloid Leukemia Revenue by Manufacturers
  2. 4.1.1 Global TKI for Chronic Myeloid Leukemia Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global TKI for Chronic Myeloid Leukemia Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global TKI for Chronic Myeloid Leukemia Sales by Manufacturers
  6. 4.2.1 Global TKI for Chronic Myeloid Leukemia Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global TKI for Chronic Myeloid Leukemia Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global TKI for Chronic Myeloid Leukemia Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global TKI for Chronic Myeloid Leukemia Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global TKI for Chronic Myeloid Leukemia Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global TKI for Chronic Myeloid Leukemia Manufacturers, Product Type & Application
  13. 4.7 Global TKI for Chronic Myeloid Leukemia Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global TKI for Chronic Myeloid Leukemia Market CR5 and HHI
  16. 4.8.2 2025 TKI for Chronic Myeloid Leukemia Tier 1, Tier 2, and Tier 3
5 TKI for Chronic Myeloid Leukemia Market by Type
  1. 5.1 Global TKI for Chronic Myeloid Leukemia Revenue by Type
  2. 5.1.1 Global TKI for Chronic Myeloid Leukemia Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Type (2021-2032)
  5. 5.2 Global TKI for Chronic Myeloid Leukemia Sales by Type
  6. 5.2.1 Global TKI for Chronic Myeloid Leukemia Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global TKI for Chronic Myeloid Leukemia Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Type (2021-2032)
  9. 5.3 Global TKI for Chronic Myeloid Leukemia Price by Type
6 TKI for Chronic Myeloid Leukemia Market by Application
  1. 6.1 Global TKI for Chronic Myeloid Leukemia Revenue by Application
  2. 6.1.1 Global TKI for Chronic Myeloid Leukemia Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global TKI for Chronic Myeloid Leukemia Revenue Market Share by Application (2021-2032)
  5. 6.2 Global TKI for Chronic Myeloid Leukemia Sales by Application
  6. 6.2.1 Global TKI for Chronic Myeloid Leukemia Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global TKI for Chronic Myeloid Leukemia Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global TKI for Chronic Myeloid Leukemia Sales Market Share by Application (2021-2032)
  9. 6.3 Global TKI for Chronic Myeloid Leukemia Price by Application
7 Company Profiles
  1. 7.1 Apotex
  2. 7.1.1 Apotex Company Information
  3. 7.1.2 Apotex Business Overview
  4. 7.1.3 Apotex TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Apotex TKI for Chronic Myeloid Leukemia Product Portfolio
  6. 7.1.5 Apotex Recent Developments
  7. 7.2 Bristol Myers Squibb
  8. 7.2.1 Bristol Myers Squibb Company Information
  9. 7.2.2 Bristol Myers Squibb Business Overview
  10. 7.2.3 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Bristol Myers Squibb TKI for Chronic Myeloid Leukemia Product Portfolio
  12. 7.2.5 Bristol Myers Squibb Recent Developments
  13. 7.3 Dr. Reddy's Laboratories
  14. 7.3.1 Dr. Reddy's Laboratories Company Information
  15. 7.3.2 Dr. Reddy's Laboratories Business Overview
  16. 7.3.3 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Dr. Reddy's Laboratories TKI for Chronic Myeloid Leukemia Product Portfolio
  18. 7.3.5 Dr. Reddy's Laboratories Recent Developments
  19. 7.4 Eugia Pharma
  20. 7.4.1 Eugia Pharma Company Information
  21. 7.4.2 Eugia Pharma Business Overview
  22. 7.4.3 Eugia Pharma TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Eugia Pharma TKI for Chronic Myeloid Leukemia Product Portfolio
  24. 7.4.5 Eugia Pharma Recent Developments
  25. 7.5 Hetero
  26. 7.5.1 Hetero Company Information
  27. 7.5.2 Hetero Business Overview
  28. 7.5.3 Hetero TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hetero TKI for Chronic Myeloid Leukemia Product Portfolio
  30. 7.5.5 Hetero Recent Developments
  31. 7.6 Lupin
  32. 7.6.1 Lupin Company Information
  33. 7.6.2 Lupin Business Overview
  34. 7.6.3 Lupin TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Lupin TKI for Chronic Myeloid Leukemia Product Portfolio
  36. 7.6.5 Lupin Recent Developments
  37. 7.7 Mylan
  38. 7.7.1 Mylan Company Information
  39. 7.7.2 Mylan Business Overview
  40. 7.7.3 Mylan TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Mylan TKI for Chronic Myeloid Leukemia Product Portfolio
  42. 7.7.5 Mylan Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Novartis TKI for Chronic Myeloid Leukemia Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Pfizer
  50. 7.9.1 Pfizer Company Information
  51. 7.9.2 Pfizer Business Overview
  52. 7.9.3 Pfizer TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Pfizer TKI for Chronic Myeloid Leukemia Product Portfolio
  54. 7.9.5 Pfizer Recent Developments
  55. 7.10 Sawai Pharmaceutical
  56. 7.10.1 Sawai Pharmaceutical Company Information
  57. 7.10.2 Sawai Pharmaceutical Business Overview
  58. 7.10.3 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Sawai Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  60. 7.10.5 Sawai Pharmaceutical Recent Developments
  61. 7.11 Sun Pharmaceuticals
  62. 7.11.1 Sun Pharmaceuticals Company Information
  63. 7.11.2 Sun Pharmaceuticals Business Overview
  64. 7.11.3 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Sun Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio
  66. 7.11.5 Sun Pharmaceuticals Recent Developments
  67. 7.12 Takeda Pharmaceuticals
  68. 7.12.1 Takeda Pharmaceuticals Company Information
  69. 7.12.2 Takeda Pharmaceuticals Business Overview
  70. 7.12.3 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Takeda Pharmaceuticals TKI for Chronic Myeloid Leukemia Product Portfolio
  72. 7.12.5 Takeda Pharmaceuticals Recent Developments
  73. 7.13 Teva
  74. 7.13.1 Teva Company Information
  75. 7.13.2 Teva Business Overview
  76. 7.13.3 Teva TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Teva TKI for Chronic Myeloid Leukemia Product Portfolio
  78. 7.13.5 Teva Recent Developments
  79. 7.14 Hansoh Pharmaceutical
  80. 7.14.1 Hansoh Pharmaceutical Company Information
  81. 7.14.2 Hansoh Pharmaceutical Business Overview
  82. 7.14.3 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Hansoh Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  84. 7.14.5 Hansoh Pharmaceutical Recent Developments
  85. 7.15 Lunan Pharmaceutical
  86. 7.15.1 Lunan Pharmaceutical Company Information
  87. 7.15.2 Lunan Pharmaceutical Business Overview
  88. 7.15.3 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Lunan Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  90. 7.15.5 Lunan Pharmaceutical Recent Developments
  91. 7.16 Qilu Pharmaceutical
  92. 7.16.1 Qilu Pharmaceutical Company Information
  93. 7.16.2 Qilu Pharmaceutical Business Overview
  94. 7.16.3 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Qilu Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  96. 7.16.5 Qilu Pharmaceutical Recent Developments
  97. 7.17 CSPC Ouyi Pharmaceutical
  98. 7.17.1 CSPC Ouyi Pharmaceutical Company Information
  99. 7.17.2 CSPC Ouyi Pharmaceutical Business Overview
  100. 7.17.3 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 CSPC Ouyi Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  102. 7.17.5 CSPC Ouyi Pharmaceutical Recent Developments
  103. 7.18 Suzhou Thery Pharmaceutical
  104. 7.18.1 Suzhou Thery Pharmaceutical Company Information
  105. 7.18.2 Suzhou Thery Pharmaceutical Business Overview
  106. 7.18.3 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  107. 7.18.4 Suzhou Thery Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  108. 7.18.5 Suzhou Thery Pharmaceutical Recent Developments
  109. 7.19 Chia Tai Tianqing Pharmaceutical
  110. 7.19.1 Chia Tai Tianqing Pharmaceutical Company Information
  111. 7.19.2 Chia Tai Tianqing Pharmaceutical Business Overview
  112. 7.19.3 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Sales, Revenue, Price and Gross Margin (2021-2026)
  113. 7.19.4 Chia Tai Tianqing Pharmaceutical TKI for Chronic Myeloid Leukemia Product Portfolio
  114. 7.19.5 Chia Tai Tianqing Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America TKI for Chronic Myeloid Leukemia Market Size by Type
  2. 8.1.1 North America TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2032)
  3. 8.1.2 North America TKI for Chronic Myeloid Leukemia Sales by Type (2021-2032)
  4. 8.1.3 North America TKI for Chronic Myeloid Leukemia Price by Type (2021-2032)
  5. 8.2 North America TKI for Chronic Myeloid Leukemia Market Size by Application
  6. 8.2.1 North America TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2032)
  7. 8.2.2 North America TKI for Chronic Myeloid Leukemia Sales by Application (2021-2032)
  8. 8.2.3 North America TKI for Chronic Myeloid Leukemia Price by Application (2021-2032)
  9. 8.3 North America TKI for Chronic Myeloid Leukemia Market Size by Country
  10. 8.3.1 North America TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America TKI for Chronic Myeloid Leukemia Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe TKI for Chronic Myeloid Leukemia Market Size by Type
  2. 9.1.1 Europe TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2032)
  3. 9.1.2 Europe TKI for Chronic Myeloid Leukemia Sales by Type (2021-2032)
  4. 9.1.3 Europe TKI for Chronic Myeloid Leukemia Price by Type (2021-2032)
  5. 9.2 Europe TKI for Chronic Myeloid Leukemia Market Size by Application
  6. 9.2.1 Europe TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2032)
  7. 9.2.2 Europe TKI for Chronic Myeloid Leukemia Sales by Application (2021-2032)
  8. 9.2.3 Europe TKI for Chronic Myeloid Leukemia Price by Application (2021-2032)
  9. 9.3 Europe TKI for Chronic Myeloid Leukemia Market Size by Country
  10. 9.3.1 Europe TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe TKI for Chronic Myeloid Leukemia Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China TKI for Chronic Myeloid Leukemia Market Size by Type
  2. 10.1.1 China TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2032)
  3. 10.1.2 China TKI for Chronic Myeloid Leukemia Sales by Type (2021-2032)
  4. 10.1.3 China TKI for Chronic Myeloid Leukemia Price by Type (2021-2032)
  5. 10.2 China TKI for Chronic Myeloid Leukemia Market Size by Application
  6. 10.2.1 China TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2032)
  7. 10.2.2 China TKI for Chronic Myeloid Leukemia Sales by Application (2021-2032)
  8. 10.2.3 China TKI for Chronic Myeloid Leukemia Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia TKI for Chronic Myeloid Leukemia Market Size by Type
  2. 11.1.1 Asia TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2032)
  3. 11.1.2 Asia TKI for Chronic Myeloid Leukemia Sales by Type (2021-2032)
  4. 11.1.3 Asia TKI for Chronic Myeloid Leukemia Price by Type (2021-2032)
  5. 11.2 Asia TKI for Chronic Myeloid Leukemia Market Size by Application
  6. 11.2.1 Asia TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2032)
  7. 11.2.2 Asia TKI for Chronic Myeloid Leukemia Sales by Application (2021-2032)
  8. 11.2.3 Asia TKI for Chronic Myeloid Leukemia Price by Application (2021-2032)
  9. 11.3 Asia TKI for Chronic Myeloid Leukemia Market Size by Country
  10. 11.3.1 Asia TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia TKI for Chronic Myeloid Leukemia Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA TKI for Chronic Myeloid Leukemia Market Size by Type
  2. 12.1.1 SAMEA TKI for Chronic Myeloid Leukemia Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA TKI for Chronic Myeloid Leukemia Sales by Type (2021-2032)
  4. 12.1.3 SAMEA TKI for Chronic Myeloid Leukemia Price by Type (2021-2032)
  5. 12.2 SAMEA TKI for Chronic Myeloid Leukemia Market Size by Application
  6. 12.2.1 SAMEA TKI for Chronic Myeloid Leukemia Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA TKI for Chronic Myeloid Leukemia Sales by Application (2021-2032)
  8. 12.2.3 SAMEA TKI for Chronic Myeloid Leukemia Price by Application (2021-2032)
  9. 12.3 SAMEA TKI for Chronic Myeloid Leukemia Market Size by Country
  10. 12.3.1 SAMEA TKI for Chronic Myeloid Leukemia Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA TKI for Chronic Myeloid Leukemia Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA TKI for Chronic Myeloid Leukemia Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 TKI for Chronic Myeloid Leukemia Value Chain Analysis
  2. 13.1.1 TKI for Chronic Myeloid Leukemia Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 TKI for Chronic Myeloid Leukemia Production Mode & Process
  6. 13.2 TKI for Chronic Myeloid Leukemia Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 TKI for Chronic Myeloid Leukemia Distributors
  9. 13.2.3 TKI for Chronic Myeloid Leukemia Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst